Exhibit 99.1

 

Joint Filing Agreement

 

The undersigned hereby agree that the Statement on Schedule 13G dated May 17, 2024 with respect to the Common Stock, $0.001 par value per share, of Pieris Pharmaceuticals, Inc., a Nevada corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

 

Dated: May 17, 2024

 

BIOTECHNOLOGY VALUE FUND, L.P.   BIOTECHNOLOGY VALUE TRADING FUND OS LP
     
By: BVF I GP LLC, its general partner      
      By: BVF Partners L.P., its investment manager
By:

/s/ Mark N. Lampert

  By: BVF Inc., its general partner
  Mark N. Lampert      
  Chief Executive Officer   By:

/s/ Mark N. Lampert

        Mark N. Lampert
        President
BVF I GP LLC      
         
By:

/s/ Mark N. Lampert

  BVF GP HOLDINGS LLC
  Mark N. Lampert      
  Chief Executive Officer   By:

/s/ Mark N. Lampert

        Mark N. Lampert
        Chief Executive Officer
BIOTECHNOLOGY VALUE FUND II, L.P.    
         
By: BVF II GP LLC, its general partner   BVF PARTNERS L.P.
         
By:

/s/ Mark N. Lampert

  By: BVF Inc., its general partner
  Mark N. Lampert      
  Chief Executive Officer   By:

/s/ Mark N. Lampert

        Mark N. Lampert
        President
BVF II GP LLC      
         
By:

/s/ Mark N. Lampert

  BVF INC.
  Mark N. Lampert      
  Chief Executive Officer   By:  
        Mark N. Lampert
        President
BVF PARTNERS OS LTD.      
         
By: BVF Partners L.P., its sole member  

/s/ Mark N. Lampert

By: BVF Inc., its general partner   MARK N. LAMPERT
         
By:

/s/ Mark N. Lampert

     
  Mark N. Lampert      
  President